In short
This article discusses clinical trials investigating the V116 pneumococcal vaccine, which contains pneumococcal polysaccharide serotype 17F conjugated to CRM197 among other serotypes. The trials aim to evaluate the safety, tolerability, and immune responses of V116 in different populations at increased risk for pneumococcal disease, including adults, children, and adolescents.
At a glance
- Study Drug
- V116 (21-valent pneumococcal conjugate vaccine)
- Target Populations
- Adults 18-64 at increased risk, Adults 50+, Children and adolescents at increased risk
- Primary Objectives
- Evaluate safety, tolerability, and immunogenicity
- Key Inclusion Criteria
- Specific risk conditions (e.g., diabetes, chronic liver/lung/heart/kidney disease)
- Primary Endpoints
- Adverse events, OPA GMTs, IgG responses
- Secondary Endpoints
- Serotype-specific immune responses, fold-rise in antibody levels
- Study Design
- Randomized, double-blind, active comparator-controlled
- Comparator
- PPSV23 (in some trials)
What is V116?
V116 is a new vaccine being developed to prevent pneumococcal disease, which is an infection caused by the bacteria Streptococcus pneumoniae. This vaccine is known as a 21-valent conjugate vaccine, which means it targets 21 different types (serotypes) of pneumococcal bacteria. The vaccine is designed to protect against some of the most common and dangerous strains of pneumococcal bacteria that can cause serious illnesses.
How Does V116 Work?
V116 works by stimulating the body's immune system to produce antibodies against specific parts of the pneumococcal bacteria. It contains small pieces of 21 different pneumococcal serotypes, each attached (or "conjugated") to a carrier protein called CRM197. This combination helps the immune system recognize and remember these bacterial components, allowing it to respond quickly if exposed to the actual bacteria in the future.
The vaccine is given as an intramuscular injection, typically in a single 0.5 ml dose. This method of administration helps ensure that the vaccine components are properly delivered to the immune system.
Who is V116 For?
V116 is being studied for use in several groups of people who are at increased risk of pneumococcal disease:
- Adults aged 18 to 64 years with certain medical conditions that increase their risk of pneumococcal infection
- Adults aged 50 years and older
- Children and adolescents with increased risk of pneumococcal disease
Some of the medical conditions that may increase a person's risk for pneumococcal disease include:
- Diabetes mellitus
- Chronic liver disease
- Chronic obstructive pulmonary disease (COPD)
- Asthma
- Chronic heart disease
- Chronic kidney disease
Clinical Trials and Research
V116 is currently being studied in several Phase 3 clinical trials. These trials are designed to evaluate the safety, tolerability, and effectiveness of the vaccine in different populations. The main goals of these studies include:
- Assessing the safety of V116 by monitoring for adverse events after vaccination
- Measuring the immune response to V116 by looking at antibody levels and other immune markers
- Comparing V116 to existing pneumococcal vaccines to see if it provides similar or better protection
Researchers are particularly interested in how well V116 stimulates the production of antibodies against the pneumococcal serotypes it targets. They measure this using tests called opsonophagocytic activity (OPA) and Immunoglobulin G (IgG) levels.
Safety and Side Effects
As with any vaccine, safety is a top priority in the development of V116. The clinical trials are carefully monitoring for any side effects or adverse events. Some of the potential side effects being studied include:
- Injection site reactions (such as pain, redness, or swelling at the injection site)
- Systemic reactions (such as fever, fatigue, or headache)
- Any serious adverse events that may be related to the vaccine
It's important to note that experiencing some mild side effects after vaccination is normal and usually indicates that your immune system is responding to the vaccine.
Potential Benefits
If proven safe and effective, V116 could offer several potential benefits:
- Protection against a wide range of pneumococcal serotypes, potentially reducing the risk of serious pneumococcal infections
- Improved immune response in people who are at higher risk of pneumococcal disease
- Possible reduction in the number of vaccine doses needed for protection compared to current vaccination schedules
However, it's important to remember that V116 is still in the research phase. More data from the ongoing clinical trials will be needed to fully understand its effectiveness and safety profile.